Changes in the gut microbiome configuration could negatively affect the response to ursodeoxycholic acid (UDCA) treatment in patients with primary biliary cholangitis (PBC), according to a recently published study in Med. “These findings suggest that baseline microbial composition may predict treatment response and offer novel insights into PBC pathogenesis,” the study concluded. UDCA represents first-line […]
Treatment with obeticholic acid (OCA) improved outcomes for primary biliary cholangitis (PBC) patients in a recent clinical trial.
A recent study found that some PBC patients face more barriers to care, leading to a delay in diagnosis and treatment.
A phase 2b clinical trial has shown positive preliminary results for volixibat intended for the treatment of PBC.
Ipsen’s Iqirvo (elafibranor) is the first new medicine approved in nearly a decade for the treatment of the PBC, according to a recent press release.
Ipsen is recruiting participants for a trial assessing the safety and efficacy of elafibranor in primary biliary cholangitis (PBC).
A recent study showed the PTPN2 gene may be associated with increased risk for primary biliary cholangitis (PBC).
The drug elafibranor appears to be effective and safe for the treatment of primary biliary cholangitis (PBC) in a phase 3 trial.
